Friday, December 9, 2011
ChemoCentryx Inc., of Mountain View, Calif., began a Phase II trial of CCX140 for diabetic kidney disease. A previous Phase II trial showed safety and tolerability in Type II diabetics on stable doses of metformin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.